Dr. Kennedy on RAS as a Target

Perry Kennedy, MD
Published: Monday, May 09, 2016



Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

RAS has been thought to be a difficult therapeutic target, Kennedy explains. Since RAS has very shallow binding pockets, it is challenging for small-molecule inhibitors to bind to and attack it.

However, an exciting component of the NCI RAS Initiative, he adds, is that researchers are actively working to attack RAS from different angles, both directly and indirectly, to better understand its behavior.



Perry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.

RAS has been thought to be a difficult therapeutic target, Kennedy explains. Since RAS has very shallow binding pockets, it is challenging for small-molecule inhibitors to bind to and attack it.

However, an exciting component of the NCI RAS Initiative, he adds, is that researchers are actively working to attack RAS from different angles, both directly and indirectly, to better understand its behavior.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in Renal Cell CarcinomaAug 31, 20181.5
Publication Bottom Border
Border Publication
x